The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

• Status: Not yet recruiting
• Trial end date: 2023-08-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue reactivity/craving and to evaluate the preliminary safety and side effects profile of suvorexant (SUVO)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston

Criteria

Inclusion Criteria:

• Meet DSM-5 criteria for MA use disorder

• Be fluent in English and able to understand the consent form

Exclusion Criteria:

• Have an alcohol use disorder or report binge drinking (>7 drinks for women and >14 drinks for men)

• Have a greater than mild substance use disorder on any other illicit substance

• Have any medical conditions contraindicating SUVO (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal ECG, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy)

• Are currently taking medications with known drug interactions with SUVO (e.g., MAO inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and any sedative)

• Are pregnant or breast feeding

• BMI > 30 (women only)

• Have a current DSM-5 psychiatric disorder or neurological disease requiring on-going treatment that would make participation unsafe

• Have history of seizure disorder

• Have a head injury with loss of consciousness in the last 5 years